This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...
HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results